Cytovac drops Danish stock market in favor of Sweden
Danish biotech company Cytovac aims to go public in Sweden within first half of this year. “The Danish stock market is simply not interesting enough,” says the CEO.
The grass is apparently greener on the other side of Oresund, at least for Danish small- and medium-sized life science firms.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Cytovac raises DKK 16 million ahead of expected IPO
For abonnenter
Cytovac ready with new strategy: IPO is an option
For abonnenter
